Cell
Volume 173, Issue 4, 3 May 2018, Pages 972-988.e23
Journal home page for Cell

Article
DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity

https://doi.org/10.1016/j.cell.2018.03.050Get rights and content
Under an Elsevier user license
open archive

Highlights

  • Endogenous networks of BRCA1, 53BP1, and MDC1 are characterized by proximity proteomics

  • Shieldin is a 53BP1 effector complex in DNA double-strand break repair

  • Vertebrate-specific shieldin is required for antibody class-switch recombination

  • Deletion of shieldin confers resistance to PARP inhibitors in BRCA1-deficient cells

Summary

Repair of damaged DNA is essential for maintaining genome integrity and for preventing genome-instability-associated diseases, such as cancer. By combining proximity labeling with quantitative mass spectrometry, we generated high-resolution interaction neighborhood maps of the endogenously expressed DNA repair factors 53BP1, BRCA1, and MDC1. Our spatially resolved interaction maps reveal rich network intricacies, identify shared and bait-specific interaction modules, and implicate previously concealed regulators in this process. We identified a novel vertebrate-specific protein complex, shieldin, comprising REV7 plus three previously uncharacterized proteins, RINN1 (CTC-534A2.2), RINN2 (FAM35A), and RINN3 (C20ORF196). Recruitment of shieldin to DSBs, via the ATM-RNF8-RNF168-53BP1-RIF1 axis, promotes NHEJ-dependent repair of intrachromosomal breaks, immunoglobulin class-switch recombination (CSR), and fusion of unprotected telomeres. Shieldin functions as a downstream effector of 53BP1-RIF1 in restraining DNA end resection and in sensitizing BRCA1-deficient cells to PARP inhibitors. These findings have implications for understanding cancer-associated PARPi resistance and the evolution of antibody CSR in higher vertebrates.

Keywords

proteomics
DNA damage repair
NHEJ
proximity labeling
shieldin
telomere maintenance
antibody class-switch recombination
53BP1
BRCA1
PARP inhibitors

Cited by (0)

7

Lead Contact